Choosing the right PV software vendor is a strategic decision. It affects patient safety, regulatory compliance, operational efficiency, and long‑term scalability.
Organisations can build in-house solutions, outsource PV operations, license commercial platforms, or adopt hybrid models. Each of these has distinct trade-offs in control, cost, time-to-live, validation burden, and global reporting capability.
This checklist outlines 11 essential criteria, from AE reporting, literature assessment, and ICSR processing to AI/automation, integration, reporting/analytics, usability, and compliance, to help you evaluate vendors systematically and select a PV platform that aligns with your company’s size, portfolio, and risk profile.
What is pharmacovigilance software?
Pharmacovigilance software is a tool used for detection, assessment, understanding, and prevention of ADRs (adverse drug reactions) or other drug-related problems. PV software supports the collection, processing, assessment, reporting, and analysis of safety information and ICSRs.
It helps to minimise the risks associated with medications, contributes to patient safety, and provides pivotal data for regulatory decision-making. When it comes to pharmacovigilance software, the primary focus is on understanding the fundamentals of ICSRs, seriousness criteria, and reporting timelines. It has system capabilities such as ICSR processing, seriousness assessment support, coding, reporting timelines, and regulatory submission. It is also important to develop a working knowledge of MedDRA terminology and to familiarise oneself with key regulatory concepts and reporting requirements from agencies such as the EMA and FDA. This helps identify how adverse reactions can sometimes occur due to drug combinations rather than single drug intake.
What does pharmacovigilance software do?
PV software is also referred to as the drug safety database or PV database. It helps pharmaceutical companies, contract research organisations (CROs), and marketing authorisation holders (MAHs) manage drug safety activities throughout a medicine’s lifetime.
It is far more complex, as it deals with heterogeneous, incomplete, and real-world safety data from multiple sources. At its core, pharmacovigilance software implements these tasks:
- Detect and manage adverse event reports (ICSRs)
- Code medical information
- Ensure regulatory compliance
- Enable signal detection and risk management
- Maintain compliance and audit readiness
Make or Buy: Build, outsource, or license?
When you are looking to adopt pharmacovigilance software in your workflow, there are three models.
They are:
- Building vs. in-house solutions
- Outsource PV solutions
- Licensing a ready-made PV platform
Building in-house solutions
Off-the-shelf PV software often fails to meet in-house requirements. By tailoring an in-house solution, you improve compliance and speed up data-driven decision-making. Developing an in-house solution allows you to strengthen the tool’s robustness and ensure it is inspection-ready. It provides greater control/customisation but also increases validation, maintenance, change control and lifecycle responsibilities.
When you develop bespoke pharmacovigilance software, it creates substantial validation, maintenance, change-control, and regulatory-update responsibilities.
It presents control/customisation as the advantage, balanced against increased validation and lifecycle-management burden. This enables you to achieve insights more quickly with AI and improve collaboration and accuracy.
Building a PV platform in-house gives you maximum control over workflows, data architecture, integrations, and customisation.
Outsource PV solutions
As per your firm’s requirements, you can outsource adverse event intake, case management, literature assessment, ICSR processing, signal detection, aggregate reporting, case intake, or quality control rather than managing everything internally.
This approach provides access to specialised PV firms, reduces internal resource requirements, and is useful if you lack advanced PV infrastructure.
Outsourcing can provide expertise and capacity but requires documented responsibilities, vendor oversight, quality agreements, and inspection readiness. When auditors or inspectors raise questions, the outsourced team needs to know what they are doing and why.
Licensing a ready-made PV platform
Licensing can be a game-changer for smaller companies, especially in the pharma and life sciences sectors. It lets you access innovation, markets, and capabilities without investing massive capital or risking building everything in-house. Licensing is particularly significant if you want to go live within months, not years. If you operate in multiple geographical regions and need proven E2B(R3) with submission capability, licensing is also beneficial.
| Option | Best suited for | Advantages | Main disadvantages |
| Build in-house | Large pharma, software companies, and highly specialised workflows. | Maximum control, custom workflows, ownership of data and IP, deep integration with internal systems. | High validation burden, long time-to-market, continuous maintenance, expensive regulatory updates, and difficult global reporting support. |
| Outsource operations | Small- and mid-sized pharma and biotech companies with fluctuating case volumes. | Access to trained case processors, medical reviewers, literature surveillance, aggregate reporting, and established procedures. | Vendor oversight remains necessary due to data and process dependency, variable quality, and transition risk. |
| License commercial software. | Most established pharma, biotech, CROs, and growing MAHs. | Faster deployment, mature workflows, regulatory reporting, audit trails, dictionaries, integrations, and vendor product updates are all key benefits. | Subscription/license cost, configuration complexity, implementation effort, and vendor lock-in. |
| License plus outsource | Startups, virtual pharma, regional MAHs, and companies that launch products quickly. | Fastest operational readiness with lower internal headcount. | Requires strong governance, quality agreements, vendor qualification, and internal PV ownership. |
11 Essential Buyer’s Checklist Points for PV Software
The following 11 criteria can help organisations evaluate whether a PV platform supports their regulatory obligations, operating model, technical environment, case volumes, and future growth. The relative importance of each criterion depends on the intended use of the system.
-
Adverse Event (AE) Reporting
Adverse event reporting is central to the pharmaceutical industry. At its heart, pharmacovigilance exists to protect patient safety by complying with regulatory requirements. However, for a PV program to operate effectively, it is crucial to promptly identify adverse events. This is why, when looking for pharmacovigilance software, it is imperative to ensure that the tool supports capture, triage, assessment, processing, and reporting of AEs/ADRs and ICSRs. It is the core engine for drug safety, protecting patients’ health and ensuring compliance with regulatory bodies such as the EMA and the FDA.
-
Literature Assessment
The buyer should assess whether the system supports literature intake/retrieval, deduplication, traceability to source, potential ICSR identification, structured extraction, human review, and integration with downstream case workflows.
-
Signal Detection and Risk Management
PV has evolved seamlessly recently. While it was once a reactive discipline, it has grown into a proactive, data-driven science. At its core lie signal detection and risk management. These two are interconnected processes that have become fundamental to ensuring patient safety while balancing benefits and potential harms.
When evaluating vendors for signal detection and risk management, buyers should prioritise partners who demonstrate multi-source data coverage (ICSRs, literature, RWE), validated and transparent statistical methods (PRR, ROR, EBGM) with documented thresholds, and robust medical-review governance by qualified safety experts.
-
Validation, Compliance & Vendor Governance
The pharmaceutical and life sciences industries are continually expanding and seeking seamless ways to do so. When selecting pharmacovigilance software, align with EMA, FDA, and TGA guidelines.
Secure time-stamped audit trails with documented, risk-based validation/qualification appropriate to intended use, with audit trails, access controls, data integrity, change control, and electronic-record/signature controls where applicable. Ensure role-based access control with unique IDs. Ensure ALCOA+ data integrity and 21 CFR Part 11–equivalent electronic records/signatures. Insist on secure, computer-generated records with unique IDs and strong authentication.
-
ICSR Case Processing
The Individual Case Safety Report (ICSR) process is a critical component of pharmacovigilance, enabling the effective detection, assessment, and management of adverse drug reactions. A well-structured and efficient ICSR management process supports drug safety and facilitates timely reporting.
Without rigorous case processing, safety data becomes unreliable. Here, an ICSR serves as a detailed report of suspected adverse reactions. It is imperative that your PV software includes case intake/creation, follow-up, duplicate management, coding, assessment, QC/review, amendment/correction, regulatory submission, acknowledgements and an audit trail to identify potential safety concerns and take pivotal actions.
-
AI & Automation Features
Regulators frame AI as an optional, risk-based capability whose value depends on clearly defined intended use, validated performance for that context, the risk level of the decisions influenced, and the strength of human oversight.
High-impact uses (e.g., causality, seriousness, signal prioritisation) should generally receive stronger validation, monitoring and human oversight depending on intended use and consequence of error, with deeper validation, continuous monitoring, and mandatory human-in-the-loop review. Whereas, lower-risk tasks may use lighter controls with periodic audits. Ensure transparency, audit trails, bias/drift monitoring, and documented governance, so AI supports, rather than replaces, expert judgement and remains inspection-ready.
-
Scalability, Reliability & Business Continuity
Effective management of ICSRs in pharmacovigilance is essential for protecting patient safety and maintaining regulatory compliance.
A dedicated safety database enables pharmacovigilance teams to capture, process, manage, and analyse safety data more efficiently and securely than spreadsheets or other non-computerised systems. By centralising safety information and supporting standardised workflows, a safety database improves data accuracy, traceability, and timeliness across pharmacovigilance operations.
You should look for system availability, performance, backup/recovery, business continuity and ability to scale with case volumes/geographies.
-
Integration Capabilities
To ensure seamless integration, pharmacovigilance software leverages standard ICH E2B(R3) to support electronic ICSR exchange, while APIs/interfaces support integration with clinical, EHR and other enterprise systems.
-
Reporting and Analytics
Reporting and analytics turn raw safety data into actionable insights, enabling timely signal detection, proactive risk management, and data-driven decision-making across PV operations.
They provide real-time visibility into case-processing performance, regulatory-timeline compliance, and quality metrics, which are critical for inspection readiness and continuous improvement. Advanced analytics, including AI-enabled signal detection and trend analysis, further enhance early warning capabilities and strategic safety oversight.
-
User Friendliness
An intuitive interface and ease of operation streamline ADR processes.
Your pharmacovigilance software should be user-friendly because poor usability directly increases processing time and leads to errors. It poses a training burden, which can compromise data quality, regulatory compliance, and ultimately patient safety.
Intuitive, role-based interfaces with streamlined workflows reduce clicks and manual steps. This enables faster case intake, coding, review, and reporting while freeing PV scientists to focus on higher-value tasks like signal assessment and benefit–risk evaluation.
-
MedDRA and WHO-DD Integration
Consistent coding underpins every pharmacovigilance activity: when two coders assign different terms to the same event, case counts fragment and signal detection becomes less reliable. To support consistent, controlled terminology, a PV system should embed the current MedDRA event dictionary with integrated browsing, auto-suggestion, and strict version control.
For medicinal products, the system should support an appropriate product dictionary, commonly WHO Drug, where applicable, while recognising that its use depends on jurisdiction, study type, and sponsor requirements rather than being universally mandatory. Equally important are documented coding conventions, trained reviewers, and structured coding review/QC processes to maintain consistency across cases, products, and dictionary versions.
EudraVigilance Screening with L2AI
L2AI is a software solution designed to automate the processing of high volumes of EudraVigilance L2A Individual Case Safety Reports (ICSRs). By leveraging advanced analytics, including machine learning and active learning, L2AI improves through controlled learning cycles, in which reviewer feedback is incorporated through a governed retraining and change-management process.
The platform automates ICSR intake (EudraVigilance L2A download), data extraction, duplicate/follow-up detection, and AI-assisted MedDRA/WHO Drug coding suggestions, but it does not make autonomous medical or regulatory decisions. All consequential assessments – validity, seriousness, expectedness, causality, final coding, and submission – require qualified human review and approval, with AI operating strictly in a propose-and-support role under documented human oversight.
L2AI can robustly handle adverse reaction reports in multiple languages and cope with synonyms, abbreviations, and spelling variations, applying these learnings to enhance the accuracy and efficiency of all future cases.
If you are looking for a solution that processes EudraVigilance L2A ICSR, L2AI is the best-fit tool.
Book a FREE DEMO of L2AI now and let’s take it further.